Deep-pocketed investors have adopted a bearish approach towards Apellis Pharmaceuticals APLS, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in APLS usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Apellis Pharmaceuticals. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 27% leaning bullish and 72% bearish. Among these notable options, 6 are puts, totaling $262,884, and 5 are calls, amounting to $246,602.
What's The Price Target?
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $55.0 to $110.0 for Apellis Pharmaceuticals over the recent three months.
Analyzing Volume & Open Interest
In terms of liquidity and interest, the mean open interest for Apellis Pharmaceuticals options trades today is 507.09 with a total volume of 650.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Apellis Pharmaceuticals's big money trades within a strike price range of $55.0 to $110.0 over the last 30 days.
Apellis Pharmaceuticals 30-Day Option Volume & Interest Snapshot
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| APLS | CALL | TRADE | BULLISH | 06/21/24 | $70.00 | $110.0K | 1.1K | 100 |
| APLS | PUT | SWEEP | BULLISH | 01/17/25 | $65.00 | $71.5K | 41 | 50 |
| APLS | CALL | SWEEP | BEARISH | 01/17/25 | $75.00 | $56.5K | 61 | 68 |
| APLS | PUT | SWEEP | BEARISH | 06/21/24 | $95.00 | $50.1K | 0 | 14 |
| APLS | PUT | SWEEP | BEARISH | 01/19/24 | $55.00 | $40.0K | 943 | 111 |
About Apellis Pharmaceuticals
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.
In light of the recent options history for Apellis Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Present Market Standing of Apellis Pharmaceuticals
- With a trading volume of 1,226,046, the price of APLS is up by 0.89%, reaching $63.5.
- Current RSI values indicate that the stock is may be approaching overbought.
- Next earnings report is scheduled for 54 days from now.
What Analysts Are Saying About Apellis Pharmaceuticals
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $67.4.
- An analyst from Oppenheimer persists with their Outperform rating on Apellis Pharmaceuticals, maintaining a target price of $75.
- An analyst from B of A Securities has elevated its stance to Buy, setting a new price target at $85.
- Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Apellis Pharmaceuticals, targeting a price of $56.
- Maintaining their stance, an analyst from Raymond James continues to hold a Strong Buy rating for Apellis Pharmaceuticals, targeting a price of $67.
- An analyst from Wells Fargo has revised its rating downward to Equal-Weight, adjusting the price target to $54.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Apellis Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
